Literature DB >> 3093967

Prospective pricing system for tertiary neonatal intensive care.

M B Resnick, M Ariet, R L Carter, J W Fletcher, J H Evans, R R Furlough, W W Ausbon, J S Curran.   

Abstract

This study assessed the potential impact of the federal neonatal diagnosis-related group (DRG) pricing system upon reimbursement to a state neonatal intensive care program. Data for length of intensive care unit stay, procedures, hospital charges, and audited cost reports from the state of Florida's ten regional neonatal intensive care centers were analyzed for 8,492 neonates whose charges totaled $118 million. Mean lengths of stay in these tertiary care centers were substantially longer than those reported for the federal DRGs, which were based on community hospital data. If federal DRG-based reimbursement to hospitals were implemented in Florida's perinatal intensive care program, compensation would range from 9% to 56% of actual hospital care charges. Federal DRG price rates were not predictive of hospital charges. Only 16% of the total variation in hospital charges was explained by differences among federal DRG rates (R2 = .16). Analysis of data by major determinants of resource consumption provided groups more homogeneous with respect to hospital charges and, hence, cost. Therefore, we developed a prospective pricing system that used modifications of federal newborn DRG system. These modifications resulted in a threefold increase in R2 (.52). Our proposed system permits prediction of cost and reimbursement for infants by three criteria: birth weight, need for mechanical ventilation and/or major surgery, and survival status and length of survival for those who die.

Entities:  

Mesh:

Year:  1986        PMID: 3093967

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  The long-term prognosis of pre-term infants: conceptual, methodological, and ethical issues.

Authors:  Linda S Siegel
Journal:  Hum Nat       Date:  1994

2.  Cost implications of different approaches to the prevention of respiratory distress syndrome.

Authors:  M Mugford; J Piercy; I Chalmers
Journal:  Arch Dis Child       Date:  1991-07       Impact factor: 3.791

3.  Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial.

Authors:  M E Backhouse; J A Mauskopf; D Jones; D E Wold; R Schumacher; R Cotton; W A Long
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

4.  Colfosceril palmitate. A pharmacoeconomic evaluation of a synthetic surfactant preparation (Exosurf Neonatal) in infants with respiratory distress syndrome.

Authors:  H M Bryson; R Whittington
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

5.  Explaining resource consumption among non-normal neonates.

Authors:  R M Schwartz; T Michelman; J Pezzullo; C S Phibbs
Journal:  Health Care Financ Rev       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.